Ladogal - Ladogal is a derivative of the synthetic steroid ethisterone, a modified testosterone. Also known as 17alpha-ethinyl testosterone. Before becoming available as a generic drug, Ladogal was marketed as Danocrine in the United States. It was approved by the U.S. Food and Drug Administration (FDA) as the first drug to specifically treat endometriosis in the early 1970s. Although effective for endometriosis, its use is limited by its masculinizing side-effects. Its role as a treatment for endometriosis has been largely replaced by the GnRH agonists.
Endometriosis as sole therapy or in conjunction with surgery to control symptoms, eg pain and pelvic tenderness and to resolve or reduce the extent of endometriotic foci. Severe cyclical mastalgia with or without nodularity (synonym: fibrocystic breast disease, mazoplasia, mastodynia) unresponsive to counseling or simple analgesics to reduce pain, tenderness and nodularity. Benign, multiple or recurrent breast cysts (synonym: Chronic cystic mastitis) to reduce the need for surgical aspiration. Dysfunctional uterine bleeding, presenting as menorrhagia (synonym: Primary menorrhagia), to control excessive blood loss and associated dysmenorrhea. Hereditary angioedema to correct partially or completely the underlying biochemical abnormality and its clinical consequences. Severe symptomatic gynecomastia, both idiopathic and drug-induced to reduce the size of the breast and to control associated pain and tenderness.
Endometriosis : Treatment of endometriosis-associated symptoms and/or to reduce the extent of endometriosis foci. Ladogal may be used either in conjunction with surgery or, as sole hormonal therapy, in patients not responding to other treatments. Benign Fibrocystic Breast Disease: Symptomatic relief of severe pain and tenderness. Ladogal should be used only in patients not responsive to other therapeutic measures or for whom such measures are inadvisable.
Endometriosis : Treatment of endometriosis-associated symptoms or/and to reduce the extent of endometriosis foci. Ladogal may be used either in conjunction with surgery or, as sole hormonal therapy, in patients not responding to other treatments. Benign Fibrocystic Breast Disease: Symptomatic relief of severe pain and tenderness. Ladogal should be used only in patients not responsive to other therapeutic measures or for whom such measures are inadvisable. Hereditary angioedema.
Indications: endometriosis, mastalgia, hereditary angioedema
Indications: endometriosis, mastalgia, gynaecomastia, hereditary angioedema, menorrhagia
Endometriosis:Danazol is indicated for the treatment of endometriosis amenable to hormonal management. Fibrocystic Breast Disease:Most cases of symptomatic fibrocystic breast disease may be treated by simple measures (e.g., padded brassieres and analgesics).In infrequent patients, symptoms of pain and tenderness may be severe enough to warrant treatment by suppression of ovarian function. Ladogal is usually effective in decreasing nodularity, pain, and tenderness. It should be stressed to the patient that this treatment is not innocuous in that it involves considerable alterations of hormone levels and that recurrence of symptoms is very common after cessation of therapy. Hereditary Angioedema:Danazol is indicated for the prevention of attacks of angioedema of all types (cutaneous, abdominal, laryngeal) in males and females.